

Lillian L Siu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4071295/publications.pdf>

Version: 2024-02-01

260
papers

20,495
citations

10986

71
h-index

11939

134
g-index

265
all docs

265
docs citations

265
times ranked

26514
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour heterogeneity in the clinic. <i>Nature</i> , 2013, 501, 355-364.	27.8	993
2	Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2001, 19, 3267-3279.	1.6	981
3	Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2004, 22, 77-85.	1.6	753
4	Dose Escalation Methods in Phase I Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2009, 101, 708-720.	6.3	678
5	Toward understanding and exploiting tumor heterogeneity. <i>Nature Medicine</i> , 2015, 21, 846-853.	30.7	604
6	The statins as anticancer agents. <i>Clinical Cancer Research</i> , 2003, 9, 10-9.	7.0	579
7	Deintensification Candidate Subgroups in Human Papillomavirus-Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis. <i>Journal of Clinical Oncology</i> , 2013, 31, 543-550.	1.6	551
8	Molecular profiling for precision cancer therapies. <i>Genome Medicine</i> , 2020, 12, 8.	8.2	447
9	Preliminary Results of a Randomized Study on Therapeutic Gain by Concurrent Chemotherapy for Regionally-Advanced Nasopharyngeal Carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 6966-6975.	1.6	420
10	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirus-Related Oropharyngeal Carcinomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 836-845.	1.6	345
11	Circulating tumor DNA and liquid biopsy in oncology. <i>Nature Cancer</i> , 2020, 1, 276-290.	13.2	309
12	Small molecules, big impact: 20 years of targeted therapy in oncology. <i>Lancet, The</i> , 2020, 395, 1078-1088.	13.7	302
13	Randomized Trial of Radiotherapy Plus Concurrent-Adjuvant Chemotherapy vs Radiotherapy Alone for Regionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1188-1198.	6.3	298
14	Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 2332-2338.	1.6	297
15	Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?. <i>Journal of Clinical Oncology</i> , 2003, 21, 1618-1623.	1.6	292
16	Comparative Prognostic Value of HPV16 E6 mRNA Compared With In Situ Hybridization for Human Oropharyngeal Squamous Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 6213-6221.	1.6	289
17	Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. <i>Journal of Clinical Oncology</i> , 2011, 29, 934-943.	1.6	280
18	Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. <i>Nature Cancer</i> , 2020, 1, 873-881.	13.2	253

#	ARTICLE	IF	CITATIONS
19	Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non-Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. <i>Journal of Clinical Oncology</i> , 2007, 25, 3978-3984.	1.6	240
20	Raf kinase as a target for anticancer therapeutics. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 677-685.	4.1	235
21	Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC. <i>JAMA Oncology</i> , 2019, 5, 195.	7.1	235
22	Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3766-3773.	1.6	230
23	Impact of the Media and the Internet on Oncology: Survey of Cancer Patients and Oncologists in Canada. <i>Journal of Clinical Oncology</i> , 2001, 19, 4291-4297.	1.6	229
24	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109.	8.2	211
25	Beyond immune checkpoint blockade: emerging immunological strategies. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 899-919.	46.4	208
26	Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval. <i>Journal of Clinical Oncology</i> , 2007, 25, 3362-3371.	1.6	198
27	Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway. <i>Journal of Clinical Oncology</i> , 2012, 30, 2919-2928.	1.6	188
28	Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 144-151.	7.0	182
29	A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 3450-3455.	7.0	180
30	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. <i>Radiotherapy and Oncology</i> , 2012, 103, 49-56.	0.6	167
31	Designing Transformative Clinical Trials in the Cancer Genome Era. <i>Journal of Clinical Oncology</i> , 2013, 31, 1834-1841.	1.6	166
32	Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 670-681.	2.6	165
33	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , 2014, 7, 1.	17.0	156
34	Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. <i>Clinical Cancer Research</i> , 2010, 16, 1726-1736.	7.0	152
35	Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 2178-2183.	1.6	138
36	Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens. <i>Journal of Clinical Oncology</i> , 2005, 23, 6982-6991.	1.6	137

#	ARTICLE	IF	CITATIONS
37	Combined-Modality Treatment of Solid Tumors Using Radiotherapy and Molecular Targeted Agents. <i>Journal of Clinical Oncology</i> , 2003, 21, 2760-2776.	1.6	131
38	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 996-1000.	3.0	128
39	Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type <i>K-RAS</i> Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2477-2484.	1.6	122
40	A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 1100-1107.	2.6	121
41	Ocular Toxicity of Targeted Therapies. <i>Journal of Clinical Oncology</i> , 2012, 30, 3277-3286.	1.6	117
42	Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 1940-1947.	1.6	116
43	PD-L1 Testing in Cancer. <i>JAMA Oncology</i> , 2016, 2, 15.	7.1	116
44	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019, 125, 1341-1349.	4.1	115
45	A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 833-839.	7.0	114
46	Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 415.	2.8	114
47	Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 1606-1621.	1.6	112
48	Analysis of Treatment Practices for Elderly Cancer Patients in Ontario, Canada. <i>Journal of Clinical Oncology</i> , 2005, 23, 3802-3810.	1.6	105
49	Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 3177-3183.	7.0	103
50	A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2011, 98, 15-22.	0.6	102
51	Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. <i>Clinical Cancer Research</i> , 2003, 9, 2478-86.	7.0	102
52	Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 225-31.	1.3	100
53	A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5526-5533.	7.0	99
54	Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. <i>European Journal of Human Genetics</i> , 2014, 22, 391-395.	2.8	98

#	ARTICLE	IF	CITATIONS
55	Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents. <i>Journal of Clinical Oncology</i> , 2006, 24, 4801-4807.	1.6	95
56	Phase I Dose Finding Studies of Obatoclox (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma. <i>Clinical Cancer Research</i> , 2010, 16, 4038-4045.	7.0	95
57	Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas. <i>Clinical Cancer Research</i> , 2011, 17, 1582-1590.	7.0	95
58	Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib. <i>Journal of Clinical Oncology</i> , 2007, 25, 2184-2190.	1.6	92
59	Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 4849-4857.	7.0	90
60	A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , 2002, 8, 2142-8.	7.0	90
61	Promising SINEs for Embargoing Nuclearâ€“Cytoplasmic Export as an Anticancer Strategy. <i>Cancer Discovery</i> , 2014, 4, 527-537.	9.4	89
62	Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay. <i>Clinical Cancer Research</i> , 2008, 14, 3441-3449.	7.0	88
63	Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. <i>International Journal of Cancer</i> , 2006, 119, 2467-2475.	5.1	87
64	Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 4260-4267.	1.6	83
65	Facilitating a culture of responsible and effective sharing of cancer genome data. <i>Nature Medicine</i> , 2016, 22, 464-471.	30.7	83
66	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. <i>Genetics in Medicine</i> , 2016, 18, 128-136.	2.4	83
67	Significance of Dysregulated Metadherin and MicroRNA-375 in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7539-7550.	7.0	82
68	Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. <i>Investigational New Drugs</i> , 2003, 21, 85-97.	2.6	81
69	Early phase clinical trials to identify optimal dosing and safety. <i>Molecular Oncology</i> , 2015, 9, 997-1007.	4.6	81
70	Randomized Phase II Trials: Inevitable or Inadvisable?. <i>Journal of Clinical Oncology</i> , 2010, 28, 2641-2647.	1.6	78
71	Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. <i>International Journal of Cancer</i> , 2013, 132, 1547-1555.	5.1	76
72	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016, 67, 174-182.	2.8	75

#	ARTICLE	IF	CITATIONS
73	Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Investigational New Drugs</i> , 2008, 26, 257-264.	2.6	74
74	Genomic testing in cancer: Patient knowledge, attitudes, and expectations. <i>Cancer</i> , 2014, 120, 3066-3073.	4.1	72
75	Phase II Study of Activated Charcoal to Prevent Irinotecan-Induced Diarrhea. <i>Journal of Clinical Oncology</i> , 2004, 22, 4410-4417.	1.6	70
76	A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). <i>Investigational New Drugs</i> , 2014, 32, 243-249.	2.6	70
77	A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. <i>Cancer</i> , 2017, 123, 4147-4157.	4.1	70
78	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2020, 6, 100.	7.1	68
79	Clinical Trials in the Elderly – A Concept Comes of Age. <i>New England Journal of Medicine</i> , 2007, 356, 1575-1576.	27.0	65
80	A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis. <i>Clinical Cancer Research</i> , 2015, 21, 68-76.	7.0	65
81	Approaches to modernize the combination drug development paradigm. <i>Genome Medicine</i> , 2016, 8, 115.	8.2	64
82	Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 220.	7.1	64
83	A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. <i>Targeted Oncology</i> , 2017, 12, 775-785.	3.6	64
84	Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. <i>European Journal of Cancer</i> , 2014, 50, 2050-2056.	2.8	63
85	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. <i>Nature Communications</i> , 2021, 12, 5137.	12.8	63
86	Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, 1570-1579.	2.8	62
87	Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges. <i>Science Advances</i> , 2022, 8, eabi8618.	10.3	61
88	Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. <i>Investigational New Drugs</i> , 2009, 27, 586-594.	2.6	59
89	Phase 1 Trial Design: Is 3 + 3 the Best?. <i>Cancer Control</i> , 2014, 21, 200-208.	1.8	59
90	Next-Generation Sequencing to Guide Clinical Trials. <i>Clinical Cancer Research</i> , 2015, 21, 4536-4544.	7.0	59

#	ARTICLE	IF	CITATIONS
91	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. <i>Clinical Cancer Research</i> , 2020, 26, 5153-5161.	7.0	58
92	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 655-663.	6.3	56
93	Treatment with pembrolizumab in programmed death ligand 1â€“positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTEâ€“28 trial. <i>Cancer</i> , 2021, 127, 1620-1629.	4.1	56
94	Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. <i>BMC Cancer</i> , 2006, 6, 263.	2.6	53
95	Tumor-NaÃ“ve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4230-4244.	7.0	53
96	Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1401-1407.	1.6	52
97	A costâ€“effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. <i>Cancer</i> , 2015, 121, 1785-1792.	4.1	51
98	Neuroendocrine Tumors of the Gastrointestinal Tract. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 64-70.	1.3	50
99	Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. <i>Current Opinion in Oncology</i> , 2008, 20, 256-263.	2.4	50
100	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 1182-1191.	2.6	50
101	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , 2019, 111, 118-128.	6.3	49
102	Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2000, 18, 4086-4097.	1.6	48
103	A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Antiâ€“Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 1348-1355.	7.0	48
104	A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. <i>Gynecologic Oncology</i> , 2017, 144, 486-490.	1.4	47
105	Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. <i>Clinical Cancer Research</i> , 2017, 23, 4950-4958.	7.0	46
106	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. <i>Oncotarget</i> , 2017, 8, 32918-32929.	1.8	46
107	A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 255-260.	1.3	45
108	A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. <i>Investigational New Drugs</i> , 2014, 32, 1269-1277.	2.6	45

#	ARTICLE	IF	CITATIONS
109	All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health. <i>Cancer Discovery</i> , 2015, 5, 1133-1136.	9.4	45
110	Are Older Cancer Patients Being Referred to Oncologists? A Mail Questionnaire of Ontario Primary Care Practitioners to Evaluate Their Referral Patterns. <i>Journal of Clinical Oncology</i> , 2003, 21, 4627-4635.	1.6	44
111	The Utility of Hedgehog Signaling Pathway Inhibition for Cancer. <i>Oncologist</i> , 2012, 17, 1090-1099.	3.7	44
112	Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. <i>Supportive Care in Cancer</i> , 2003, 11, 41-47.	2.2	42
113	Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies. <i>Targeted Oncology</i> , 2019, 14, 43-55.	3.6	42
114	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. <i>Cancer</i> , 2020, 126, 3426-3437.	4.1	42
115	Use of mesna to prevent ifosfamide-induced urotoxicity. <i>Supportive Care in Cancer</i> , 1998, 6, 144-154.	2.2	40
116	Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 814, 143-147.	2.3	40
117	Brivanib alaninate for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 577-586.	4.1	39
118	An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE). , 2019, 7, 72.		38
119	HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2021, 27, 5857-5868.	7.0	38
120	Rationale for Ras and Raf-kinase as a Target for Cancer Therapeutics. <i>Current Pharmaceutical Design</i> , 2002, 8, 2231-2242.	1.9	37
121	Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 154-160.	2.3	37
122	Epidermal Growth Factor Receptor Targeting in Head and Neck Cancer: Have We Been Just Skimming the Surface?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1381-1383.	1.6	36
123	A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187. <i>Investigational New Drugs</i> , 2016, 34, 450-457.	2.6	36
124	Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 261-273.	2.8	36
125	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883.		36
126	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. <i>Future Oncology</i> , 2020, 16, 1235-1243.	2.4	36

#	ARTICLE	IF	CITATIONS
127	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. <i>Investigational New Drugs</i> , 2015, 33, 652-663.	2.6	35
128	Sharing Clinical and Genomic Data on Cancer – The Need for Global Solutions. <i>New England Journal of Medicine</i> , 2017, 376, 2006-2009.	27.0	35
129	A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 1016-1025.	2.6	34
130	Vinblastine and erythromycin: an unrecognized serious drug interaction. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 35, 188-190.	2.3	33
131	Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination. <i>Clinical Cancer Research</i> , 2006, 12, 2141-2149.	7.0	33
132	A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2793-2802.	1.3	33
133	A multicenter phase 1 study of β -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 169-176.	2.6	32
134	The Future of Clinical Trial Design in Oncology. <i>Cancer Discovery</i> , 2021, 11, 822-837.	9.4	32
135	The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial. <i>Supportive Care in Cancer</i> , 2007, 15, 829-840.	2.2	31
136	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020, 126, 4936-4947.	4.1	31
137	Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2000, 18, 3677-3689.	1.6	30
138	Troxacitabine, an l-Stereoisomeric Nucleoside Analog, on a Five-Times-Daily Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2002, 20, 96-109.	1.6	30
139	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. <i>Radiotherapy and Oncology</i> , 2020, 144, 13-22.	0.6	30
140	First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 57-70.	7.0	30
141	Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. <i>Drug Resistance Updates</i> , 2008, 11, 99-109.	14.4	29
142	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2014, 32, 1005-1016.	2.6	29
143	TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 346-352.	2.5	29
144	Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 858-867.	7.0	28

#	ARTICLE	IF	CITATIONS
145	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 159-168.	2.5	27
146	Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. , 2020, 8, e001095.		27
147	Development of the Functional Assessment of Cancer Therapyâ€“Immune Checkpoint Modulator (FACTâ€“ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020, 126, 1550-1558.	4.1	26
148	Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 71-79.	2.2	26
149	A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. <i>Investigational New Drugs</i> , 2007, 25, 217-225.	2.6	25
150	Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?. <i>BMC Cancer</i> , 2011, 11, 426.	2.6	25
151	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021, 113, 980-988.	6.3	25
152	A phase II study of temozolomide in advanced untreated pancreatic cancer. <i>Investigational New Drugs</i> , 1998, 16, 77-79.	2.6	24
153	Adherence to Surveillance Guidelines After Curative Resection for Stage II/III Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 191-196.	2.3	24
154	Molecular targeted therapies in all histologies of head and neck cancers: an update. <i>Current Opinion in Oncology</i> , 2010, 22, 212-220.	2.4	24
155	A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2011, 29, 996-1003.	2.6	24
156	Designing circulating tumor DNA-based interventional clinical trials in oncology. <i>Genome Medicine</i> , 2019, 11, 22.	8.2	24
157	Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions. <i>Current Pharmaceutical Design</i> , 2005, 11, 265-272.	1.9	24
158	Reporting of Time-to-Event End Points and Tracking of Failures in Randomized Trials of Radiotherapy With or Without Any Concomitant Anticancer Agent for Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5965-5971.	1.6	23
159	Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. <i>International Journal of Cancer</i> , 2018, 142, 57-65.	5.1	23
160	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , 2019, 24, e146-e148.	3.7	23
161	A Phase I Study of Dinaciclib in Combination With MKâ€“2206 in Patients With Advanced Pancreatic Cancer. <i>Clinical and Translational Science</i> , 2020, 13, 1178-1188.	3.1	23
162	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. <i>Radiotherapy and Oncology</i> , 2021, 165, 94-102.	0.6	22

#	ARTICLE	IF	CITATIONS
163	A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. <i>Clinical Cancer Research</i> , 2002, 8, 2157-66.	7.0	22
164	Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units. <i>Investigational New Drugs</i> , 1998, 16, 113-119.	2.6	21
165	Phase I and Pharmacokinetic Study of Novel I-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 Days. <i>Journal of Clinical Oncology</i> , 2002, 20, 2567-2574.	1.6	21
166	The Contents and Readability of Informed Consent Forms for Oncology Clinical Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 387-392.	1.3	21
167	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials. <i>Oncologist</i> , 2015, 20, 653-659.	3.7	21
168	Cancer patientsâ€™ experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , 2020, 9, 3015-3022.	2.8	21
169	First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3452-3463.	7.0	21
170	Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1247-1254.	4.1	20
171	Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 751-760.	4.1	20
172	Magnetic resonance imaging of nasopharyngeal carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 365-375.	2.4	20
173	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Nonâ€“Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2117547.	5.9	20
174	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. , 2021, 9, e003476.		20
175	Lung cancer in never smokers from the Princess Margaret Cancer Centre. <i>Oncotarget</i> , 2018, 9, 22559-22570.	1.8	20
176	Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents. <i>Journal of Clinical Oncology</i> , 2008, 26, 1324-1330.	1.6	19
177	FcÎ³ receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. <i>Cancer Medicine</i> , 2018, 7, 5478-5487.	2.8	19
178	Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). <i>British Journal of Cancer</i> , 2021, 124, 1543-1551.	6.4	19
179	Quality of life in patients with Kâ€“RAS wild-type colorectal cancer. <i>Cancer</i> , 2014, 120, 181-189.	4.1	18
180	Precision Medicine in Head and Neck Cancer: Myth or Reality?. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491877958.	1.3	18

#	ARTICLE	IF	CITATIONS
181	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCIâ™9041). <i>Investigational New Drugs</i> , 2016, 34, 104-111.	2.6	17
182	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. <i>Clinical Colorectal Cancer</i> , 2018, 17, 73-79.	2.3	17
183	Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <i>PLoS ONE</i> , 2021, 16, e0253070.	2.5	17
184	A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer. <i>Oral Oncology</i> , 2016, 59, 43-49.	1.5	16
185	Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort. <i>Head and Neck</i> , 2018, 40, 2029-2042.	2.0	16
186	Additional germline findings from a tumor profiling program. <i>BMC Medical Genomics</i> , 2018, 11, 65.	1.5	16
187	Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era. <i>European Journal of Cancer</i> , 2021, 158, 85-98.	2.8	16
188	Telomerase: Therapeutic Potential in Cancer. <i>Cancer Investigation</i> , 2000, 18, 269-277.	1.3	15
189	Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics. <i>Cancer Treatment Reviews</i> , 2021, 92, 102125.	7.7	15
190	Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. <i>Investigational New Drugs</i> , 2021, 39, 1587-1597.	2.6	15
191	Phase I and Pharmacokinetic Study of the Differentiating Agent Vesnarinone in Combination With Gemcitabine in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 3974-3985.	1.6	14
192	A Multicenter Phase II Study of "Adjuvant" Irinotecan Following Resection of Colorectal Hepatic Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 547-554.	1.3	14
193	Clinical genomics information management software linking cancer genome sequence and clinical decisions. <i>Genomics</i> , 2013, 102, 140-147.	2.9	14
194	Cancer genomics. <i>Current Opinion in Oncology</i> , 2015, 27, 250-257.	2.4	14
195	Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. <i>Clinical Cancer Research</i> , 2017, 23, 4020-4026.	7.0	14
196	Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 167-171.	2.5	14
197	Impact of cisplatin dose and smoking pack-years in human papillomavirus"positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , 2019, 118, 112-120.	2.8	14
198	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa115.	2.9	14

#	ARTICLE	IF	CITATIONS
199	Cancer Clinical Trials: The Rear-View Mirror and the Crystal Ball. <i>Cell</i> , 2017, 168, 575-578.	28.9	13
200	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. <i>Investigational New Drugs</i> , 2020, 38, 1774-1783.	2.6	13
201	Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. <i>Oncotarget</i> , 2017, 8, 84659-84670.	1.8	13
202	Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3372-3374.	1.6	12
203	Utilization of tumor genomics in clinical practice: an international survey among ASCO members. <i>Future Oncology</i> , 2019, 15, 2463-2470.	2.4	12
204	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa122.	2.9	12
205	All is not lost: learning from 9p21 loss in cancer. <i>Trends in Immunology</i> , 2022, 43, 379-390.	6.8	12
206	A Risk-Benefit Assessment of Irinotecan in Solid Tumours. <i>Drug Safety</i> , 1998, 18, 395-417.	3.2	11
207	Targeting the Hedgehog Pathway in Cancer: Can the Spines Be Smoothened?. <i>Clinical Cancer Research</i> , 2011, 17, 2071-2073.	7.0	11
208	Less Than Ideal: How Oncologists Practice With Limited Drug Access. <i>Journal of Oncology Practice</i> , 2012, 8, 190-195.	2.5	11
209	Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e98557.	2.5	11
210	Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 763-765.	1.4	11
211	Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT). <i>Investigational New Drugs</i> , 2015, 33, 895-900.	2.6	11
212	Increasing operational and scientific efficiency in clinical trials. <i>British Journal of Cancer</i> , 2020, 123, 1207-1208.	6.4	11
213	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 298-301.	10.7	11
214	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K β , in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2257-2269.	7.0	11
215	Improving the Quality of Abstract Reporting for Phase I Cancer Trials. <i>Clinical Cancer Research</i> , 2008, 14, 1782-1787.	7.0	10
216	CanDIG: Federated network across Canada for multi-omic and health data discovery and analysis. <i>Cell Genomics</i> , 2021, 1, 100033.	6.5	10

#	ARTICLE	IF	CITATIONS
217	Hepatic steatosis secondary to capecitabine: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 227.	0.8	9
218	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). <i>Investigational New Drugs</i> , 2016, 34, 575-583.	2.6	9
219	Determinants of the recommended phase 2 dose of molecular targeted agents. <i>Cancer</i> , 2017, 123, 1409-1415.	4.1	9
220	The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 39.	3.0	9
221	Rational design and identification of immuno-oncology drug combinations. <i>European Journal of Cancer</i> , 2018, 95, 38-51.	2.8	9
222	Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 334-341.	2.3	9
223	Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 51.	8.6	9
224	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , 2020, 105, 104666.	1.5	8
225	The Influence of Mentorship on Research Productivity in Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 549-555.	1.3	7
226	Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI-853520. <i>Targeted Oncology</i> , 2019, 14, 67-74.	3.6	7
227	Early detection of treatment futility in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2022, 13, 61-72.	1.8	7
228	Clinical trials and biomarker development with molecularly targeted agents and radiotherapy. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 339-349.	5.9	6
229	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2020, 26, 5329-5337.	7.0	6
230	The Day After COVID-19—Time to Rethink Oncology Clinical Research. <i>JAMA Oncology</i> , 2021, 7, 23.	7.1	6
231	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , 2020, 9, 337.	1.6	6
232	Circulating Biomarkers for Therapeutic Monitoring of Anti-cancer Agents. <i>Oncologist</i> , 2022, 27, 352-362.	3.7	6
233	Testing <i>ERBB2</i> p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001016.	1.2	5
234	Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. <i>Clinical Colorectal Cancer</i> , 2019, 18, e140-e149.	2.3	5

#	ARTICLE	IF	CITATIONS
235	Two-Target Quantitative PCR To Predict Library Composition for Shallow Shotgun Sequencing. <i>MSystems</i> , 2021, 6, e0055221.	3.8	5
236	Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3504-3504.	1.6	5
237	Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , 2019, 37, 2542-2542.	1.6	5
238	Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2005, 23, 455-465.	2.6	4
239	PS-139-Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <i>Journal of Hepatology</i> , 2019, 70, e89.	3.7	4
240	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz071.	2.9	4
241	Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials. <i>Oncologist</i> , 2022, 27, e286-e293.	3.7	4
242	Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation. <i>Cancer Research Communications</i> , 2022, 2, 39-48.	1.7	4
243	Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. , 2022, 10, e004378.		4
244	Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors. <i>Anti-Cancer Drugs</i> , 2006, 17, 81-87.	1.4	3
245	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 994-1002.	0.8	3
246	A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3082-3082.	1.6	3
247	A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. <i>Targeted Oncology</i> , 2022, 17, 271-281.	3.6	3
248	Reply to D.J. Stewart. <i>Journal of Clinical Oncology</i> , 2010, 28, e651-e651.	1.6	2
249	Cancer patientsâ€™ acceptability of incorporating an epidemiology questionnaire within a clinical trial. <i>Clinical Trials</i> , 2015, 12, 237-245.	1.6	2
250	Giant Prolactinoma Presenting As a Base of Skull Tumor With Nasopharyngeal Extension: A Potential Diagnostic Pitfall in Neuroendocrine Lesions of the Base of Skull. <i>Head and Neck Pathology</i> , 2017, 11, 537-540.	2.6	2
251	Innovation and Advances in Precision Medicine in Head and Neck Cancer. , 2021, , 355-373.		2
252	A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS5600-TPS5600.	1.6	2

#	ARTICLE	IF	CITATIONS
253	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. <i>Oncologist</i> , 2019, 24, e518-e525.	3.7	1
254	Using real-word data to evaluate the effects of broadening eligibility criteria in oncology trials. <i>Cancer Cell</i> , 2021, 39, 750-752.	16.8	1
255	Selecting the Best Drugs for Phase I Clinical Development and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 469-473.	3.8	1
256	A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3057-3057.	1.6	1
257	Important Early Advances in Squamous Cell Carcinoma of the Head and Neck. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 373-376.	3.8	1
258	Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3027-3027.	1.6	1
259	Characterization and outcomes of patients enrolled to multiple phase I cancer trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 469-472.	2.3	0
260	Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 3572-3572.	1.6	0